Healthcare Services

Hemophilia Market Revenue Growth Expected to Reach $23.16 Billion by 2030 with 9.3% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Hemophilia Market In 2026 And What Value Is Projected For 2030?

The hemophilia market has seen significant expansion in recent years. Its valuation is predicted to increase from $14.98 billion in 2025 to $16.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical growth can be ascribed to improved availability of clotting factor concentrates, expansion of prophylactic treatment adoption, growth in hemophilia awareness programs, advancements in recombinant factor production, and increased access to specialized care centers.

The hemophilia market is poised for substantial expansion over the next few years, with projections indicating it will reach $23.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.3%. This anticipated growth can be attributed to several factors, including the increasing number of gene therapy approvals, a rising preference for personalized treatment approaches, the broadening availability of home infusion programs, escalating investments in rare disease research, and a heightened emphasis on improving patients’ quality of life. Key trends expected in the forecast period encompass the greater adoption of long-acting clotting factor therapies, an intensified focus on gene therapy specifically for hemophilia, the increasing utilization of home-based treatment regimens, the expansion of personalized prophylactic treatment plans, and enhanced integration of digital patient monitoring solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12905&type=smp

What Drivers Are Influencing The Hemophilia Market?

The increasing incidence of genetic abnormalities is anticipated to fuel the expansion of the hemophilia market in the future. Genetic abnormalities, alternatively termed genetic mutations or disorders, are defined as alterations in an individual’s gene DNA sequence, potentially leading to diverse health issues and physical characteristics. The goal of hemophilia treatment is to avert or manage bleeding episodes, lessen complications, and enhance the quality of life for those affected by these genetic conditions. For example, data from October 2024, provided by Cystic Fibrosis Trust, a UK-based organization assisting individuals with cystic fibrosis, showed approximately 11,148 cystic fibrosis (a genetic disorder) patients registered in 2022, a figure that climbed to 11,318 by 2023, indicating a 1.5% year-over-year rise in patient registrations. Consequently, the growing prevalence of genetic abnormalities is propelling the expansion of the hemophilia market.

What Are The Key Segments Of The Hemophilia Market?

The hemophilia market covered in this report is segmented –

1) By Type: Hemophilia A, Hemophilia B, Hemophilia C, Other Types

2) By Treatment: Replacement Therapy, Hemostatic Agents, Desmopressin, Gene Therapy, Other Treatments

3) By End-User: Hospitals, Clinics, Home Care Settings, Other End-Users

Subsegments:

1) By Hemophilia A: Severe Hemophilia A, Moderate Hemophilia A, Mild Hemophilia A

2) By Hemophilia B: Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B

3) By Hemophilia C: Severe Hemophilia C, Mild Hemophilia C

4) By Other Types: Acquired Hemophilia, Von Willebrand Disease

Which Trends Are Shaping The Future Of The Hemophilia Market?

Leading companies in the hemophilia sector are developing advanced medications such as ALTUVIIIO to maintain their market presence. For instance, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, introduced ALTUVIIIO for hemophilia, which was approved by The Food and Drug Administration (FDA), a US-based government agency. With its once-weekly dosing, ALTUVIIIO is the first and only hemophilia A medication to provide regular to near-normal factor activity levels (above 40%) for most of the week and significantly reduce bleeding compared to previous factor VIII prophylaxis.

Who Are The Leading Companies Operating In The Hemophilia Market?

Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Dimension Therapeutics, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB, Chiesi Farmaceutici S.p.A.

Read the full hemophilia market report here:

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Hemophilia Market?

North America was the largest region in the hemophilia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hemophilia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12905&type=smp

Browse Through More Reports Similar to the Global Hemophilia Market 2026, By The Business Research Company

Hepatitis Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Acquired Hemophilia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Hemostasis Products Global Market Report

https://www.thebusinessresearchcompany.com/report/hemostasis-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795